status is none of yer' damn business!! :-)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Global cell phone use at 50 percent
Thu Nov 29, 2007 12:42pm EST
(Reuters) - Worldwide mobile telephone subscriptions reached 3.3 billion -- equivalent to half the global population -- on Thursday, 26 years after the first cellular network was launched, research firm Informa said.
Since the first Nordic Mobile Telephony (NMT) networks were switched on in 1981 in Saudi Arabia, Sweden and Norway, mobile phones have become the consumer electronics sector with the largest volume of sales in the world.
"The mobile industry has constantly outperformed even the most optimistic forecasts for subscriber growth," Mark Newman, head of research at Informa said in a statement.
"For children growing up today the issue is not whether they will get a mobile phone, it's a question of when," Newman said.
In recent years the industry has seen surging growth in outskirts of China and India, helped by constantly falling phone and call prices, with cellphone vendors already eyeing inroads into Africa's countryside to keep up the growth.
The Nordic start for mobile telephony was the basis for the success stories of Finnish Nokia (NOK1V.HE) and Sweden's Ericsson (ERICb.ST).
Fast growth in Asian wireless markets has since helped Korean Samsung Electronics (005930.KS) and LG Electronics (066570.KS) as well as China's ZTE (0763.HK) take their place among the top six cellphone vendors globally.
But although mobile subscriptions have reached the equivalent of 50 percent of the population, this does not mean that half the people in the world now have a mobile phone, since Informa said 59 countries have mobile penetration of over 100 percent -- where some owners have more than one phone.
"The economic difference between the more mature markets and those in developing countries is highlighted by the vast differences in operators' revenues per user," Informa said.
Hutchison Whampoa's (0013.HK) 3 operation has an average revenue per user of just over $70 a month in Britain, while Hutchison's Sri Lankan operator counts revenues of below $3 per user.
According to the International Programs Center of the U.S. Census Bureau, the total population of the world reached 6,634,294,193 on Thursday.
At the same time 2,571,563,279 people were using the most widely used mobile technology, GSM (Global System for Mobile communications), according to global trade body GSM Association.
The second largest mobile technology, CDMA, had 421.4 million users at end September.
(Reporting by Tarmo Virki)
You just might be right there Stevo. Maybe we wil get a nice storng close here.
Be careful with it. JMO.
That is Steve Carnes right?
Yep, they should get some action off of that news.
Some would say that. LOL.
GERN
US approves 1st stem cell study for spinal injury
By MALCOLM RITTER, AP Science Writer Malcolm Ritter, Ap Science Writer – Fri Jan 23, 12:03 am ET
NEW YORK – A U.S. biotech company says it plans to start this summer the world's first study of a treatment based on human embryonic stem cells — a long-awaited project aimed at spinal cord injury.
The company gained federal permission this week to inject eight to 10 patients with cells derived from embryonic cells, said Dr. Thomas Okarma, president and CEO of Geron Corp. of Menlo Park, Calif.
The patients will be paraplegics, who can use their arms but can't walk. They will receive a single injection within two weeks of their injury.
The study is aimed at testing the safety of the procedure, but doctors will also look for signs of improvement like return of sensation or movement in the legs, Okarma said.
Whatever its outcome, the study will mark a new chapter in the contentious history of embryonic stem cell research in the United States — a field where debate spilled out of the laboratory long ago and into national politics.
While some overseas doctors claim to use human embryonic stem cells in their clinics, stem cell experts said they knew of no previous human studies that use such cells.
"It's a milestone and it's a breakthrough for the field" because Geron passed the safety hurdles for getting federal clearance to launch the study, said Ed Baetge, chief scientific officer of Novocell Inc. His company hopes to begin a similar human study for treating diabetes in a few years.
In addition, said spinal cord injury researcher Dr. Wise Young of Rutgers University, "a lot of hope of the spinal cord injury community is riding on this trial."
Embryonic stem cells can develop into any cell of the body, and scientists have long hoped to harness them for creating replacement tissues to treat a variety of diseases. But research has been controversial because embryos must be destroyed to obtain them.
President Barack Obama has promised to relax the Bush administration's restrictions on federal financing for such research. But Obama's ascent to the White House had nothing to do with the U.S. Food and Drug Administration's granting permission for the new study, Okarma said in a telephone interview Thursday.
In fact, the company says, the project involves stem cells that were eligible for federal funding under Bush, although no federal money was used to develop the experimental treatment or to pay for the human study.
Other human cells, called adult stem cells, have been tested before in people to treat heart problems, for example.
In the Geron study, the injections will be made in the spine at the site of damage. The work will be done in four to seven medical centers around the country, Okarma said.
Animal studies suggest that once injected, the cells will mature and repair what is essentially a lack of insulation around damaged nerves, and also pump out substances that nerves need to function and grow.
Apart from assessing safety, investigators will hope to see some signs of improvement in the patient, Okarma said. The idea is "not to make somebody ... get up and dance the next day," he said, but rather to provide some level of ability that can be improved by physical therapy.
Each patient will receive a low dose of anti-rejection drugs for about two months, because after that time the medications shouldn't be needed, Okarma said. The study will follow each patient for at least a year.
Okarma said he can't estimate how much such a therapy would cost if it proves effective, but that "this is not going to be a $500,000 price tag. It will be remarkably affordable ... in the context of the value it provides."
Evan Snyder, a stem cell researcher at the Burnham Institute for Medical Research in La Jolla, Calif., said scientists in the field will focus chiefly on the study's results about safety.
"The one hope that everybody has is that nothing bad happens," he said.
Geron Corp. has spent at least $100 million on human embryonic stem cell research. Founded in 1992, it does not have any therapies on the market.
However, the company is considered the world's leading embryonic stem cell developer thanks to its claims on several key stem cell technologies. Geron helped finance researchers at the University of Wisconsin who first isolated human embryonic stem cells in 1998. The company has retained exclusive rights on several of those cell types.
http://news.yahoo.com/s/ap/20090123/ap_on_sc/sci_stem_cells
Would be nice. I think we have a lot of fence sitters waiting on that A/S reduction to be completed.
Now the gap has been filled we can move on.
.05 WILL be the low. I am willing it so!!!!
Whole market sucking arse!!!
Sure do.
On April 20, 2008, we entered into an exclusive purchasing and marketing
agreement ("Agreement") with Al-Sadeef Trading Company (headquartered in Jordan)
and its shareholders Mr. Tahseen Jasim Hamadi and Mr. Ali Jasim Hamadi
(collectively: the "Buyer") for the purchase, sale and marketing of our Yogen
product in the Middle East. Pursuant to the terms of the agreement, the Buyer
agreed to purchase a minimum of 300,000 units of the Yogen product per year for
a price per unit equal to the manufacturing price plus 30%, including all
shipment expenses incurred by us. The Agreement is filed as exhibit 10.1 to this
Quarterly Report on Form 10-Q and is incorporated herein by reference. We expect
to receive the first order in the coming days and under the Agreement we will be
obligated to use reasonable efforts to manufacture and ship the products within
90 days from acceptance of such order.
Could get a good bounce once it does fill.
We should, especially once the production starts.
Looks like PURO gonna fill the gap.
Sure is a lot of coverage.
Yeah most are indicating oversold but the darned thing keeps making new 52 week lows. Will mantain a close eye on it.
Oh ok, it's a standard disclosure. Though I missed something.
Good idea lucky. Infomercials would be a good way to kick things off.
Your point?
Yep, where you think bottom is at?
SmallCapReview - Stocks on the Move - IWOV, ESYE, EAT
Easy Energy (OTCBB: ESYE) Trading at $0.082, Up 9%. Today announced that it has completed the finalization of the design of its YoGen Max(TM), a compact foldable manpowered charger for laptop computers and other like-sized devices.
The YoGen Max(TM) will enable Easy Energy to service the extremely large and growing market for chargers capable of handling portable electronic devices of 50-60 W, i.e. primarily laptop and notebook computers. The YoGen Max(TM) is designed to be conveniently foot operated. The user will be able to produce sufficient power to operate their laptop and charge its battery in an uninterrupted fashion, without detracting from their ability to simultaneously work on their computer, by pressing down on a springy, suspended, self-returning pedal.
When not in use, the YoGen Max(TM) folds up into a compact book-sized package. The breakthrough level of performance characteristic of the YoGen® line of manpowered chargers, which has made them a viable economical source of green alternative energy, is enabled by dramatically innovative advances in several aspects of both the device's mechanism which converts linear motion into rotary motion and the uniquely efficient alternator and electronic controller.
What They Do: Easy Energy is the sole owner of the YoGen® product suite of compact man-powered generators, which are designed to provide an innovative and effective solution to the currently underserved need of the almost limitless users of portable electronics devices for a power source that will ensure those devices' ability to operate in circumstances in which conventional recharging sources are unavailable.
How They Trade: ESYE has a 52 week high of $0.36 and a 52 week low of $0.02.
Stockguru.com: Stocks to Watch for January 23, 2009 - ESYE, SSHO, SPCK, AWEC, LLFH, and AMLJ
Jan 23, 2009 (M2 PRESSWIRE via COMTEX) -- SPCK | Quote | Chart | News | PowerRating -- Our Stocks to Watch today include : Easy Energy Inc (OTCBB: ESYE), South Shore Resources Inc. (OTCBB: SSHO), Superclick Inc. (OTCBB: SPCK), Ameriwest Energy Corp. (OTCBB: AWEC), L & L International Holdings, Inc. (OTCBB: LLFH), and AML Communications Inc. (OTCBB: AMLJ)
Visit: http://www.stockguru.com/joinfree.html to register for our daily Stocks to Watch and Trade Alerts.
Easy Energy Inc (OTCBB: ESYE | Quote | Chart | News | PowerRating) Shares traded up 6.67% at $0.08
Easy Energy, Inc. is the sole owner of the YoGen product suite of compact man-powered generators, which are designed to provide an innovative and effective solution to the currently underserved need of the almost limitless users of portable electronics devices for a power source that will ensure those devices' ability to operate in circumstances in which conventional recharging sources are unavailable. Included in the product line are the basic YoGen , a slim, pocket-sized charger for small devices such as cell phones, GPS, iPODs, etc., which is operated by a convenient pull-cord; the YoGen Max(TM), a compact, fold-up foot-driven charger for laptop computer sized devices which also includes its own battery pack; and the most recently prototyped YoGen Bat(TM), which will replace a conventional cell phone battery and provide pull-cord charging capability without the need for a stand-alone charger. The company is headquartered in Las Vegas, Nevada with offices in Naariya, Israel.
ESYE News Yesterday, Easy Energy completed the finalization of the design of its YoGen Max(TM), a compact foldable manpowered charger for laptop computers and other like-sized devices. The YoGen Max(TM) will enable Easy Energy to service the extremely large and growing market for chargers capable of handling portable electronic devices of 50-60 W, i.e. primarily laptop and notebook computers. The YoGen Max(TM) is designed to be conveniently foot operated. The user will be able to produce sufficient power to operate their laptop and charge its battery in an uninterrupted fashion, without detracting from their ability to simultaneously work on their computer, by pressing down on a springy, suspended, self-returning pedal. The design of the pedal mechanism and efficiency of the generator allow for long-term operation at the required wattage without significant user fatigue.
Nice action so far for sure.
Don't know but someone wanted some.
Man, some nice volume to start the day today.
Very nice information there gofor. Thanks for getting this for everyone here. Mr Ofir has big expectations to say he expects 750K units to be sold in 2009. That would be a HUGE accomplishment.
Morning people.
ESYE - Like that one as well Pastor. Reducing the AS almost 10 fold is a big plus. Just waiting on that to get finalized and it should see a nice gain. Not to mention produciton starting in March.
Good mornig folks. Looks like it's going to be another shatty day in the markets.
Morning people.
Morning people.
I am sure they will.
LOL, well maybe it won't fill that one right?
That gap at .05 and.06 seems to be calling.
Perfect for the Yogen Max.
Woud be a great gift. Now the comapny just has to produce them.
If they can get this in full blown production you can bet they will.